| Ytd | -28.92% | |
| 1y | -75.19% |
| Open | 11.38 | Prev Close | 11.56 | Low | 11.14 | High | 11.55 | Mkt Cap | 184.28M |
| Vol | 86.67K | Avg Vol | 507.14K | EPS | -14.36 | P/E | -0.81 | Forward P/E | -0.01 |
| Beta | 1.64 | Short Ratio | 0.35 | Inst. Own | 0.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 12.46 | 200-d Avg | 15.32 | 1yr Est | 5.83 |
TNXP News
Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003
Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or "the Company"), a full
New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of appr
HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluat
Top Wall Street analysts changed outlook on top names. See all changes incl. upgrades, downgrades &a
Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Analysts changed outlook on top names, including Intel and Arrow Financial. See ratings page. TNXP s
Raymond James analyst Tiago Fauth initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with
BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasda
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are trading higher Monday after the company
Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides
Real-world analysis of three years of closed claims data from Symphony Health, focused on the third
Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-
Real-world analysis of three years of closed claims data from Symphony Health focused on the third y
BERKELEY HEIGHTS, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq
BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq
In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patient
Agreement with leading group purchasing organization (GPO) provides access to approximately 35 milli
Company on track to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field
TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significan
TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime, is the first
TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a
Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models an
During Thursday's session, 406 companies made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% o
On Wednesday, 807 companies reached new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Gainers Synthetic Biologics, Inc. (NYSE: SYN) shares climbed 100% to close at $1.00 on Tuesday af
Stocks That Hit 52-Week Lows On Tuesday